Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
33.21
+0.07 (0.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
Apellis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 715.22 | 396.59 | 75.42 | 66.56 | 250.65 | - | Upgrade
|
| Revenue Growth (YoY) | 162.10% | 425.83% | 13.31% | -73.44% | - | - | Upgrade
|
| Cost of Revenue | 417.28 | 412.9 | 392.87 | 426.07 | 25.05 | 220.97 | Upgrade
|
| Gross Profit | 297.94 | -16.31 | -317.45 | -359.51 | 225.6 | -220.97 | Upgrade
|
| Selling, General & Admin | 521.27 | 500.82 | 277.16 | 176.77 | 139.4 | 67.05 | Upgrade
|
| Research & Development | - | - | - | - | 299.92 | - | Upgrade
|
| Operating Expenses | 521.27 | 500.82 | 277.16 | 176.77 | 439.32 | 67.05 | Upgrade
|
| Operating Income | -223.33 | -517.12 | -594.61 | -536.28 | -213.73 | -288.02 | Upgrade
|
| Interest Expense | -36.26 | -29.58 | -32.63 | -13.24 | -29.94 | -5.29 | Upgrade
|
| Interest & Investment Income | 13.93 | 20.93 | 8.91 | 0.42 | 4.16 | 5.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.19 | -0.73 | -0.29 | -96.31 | -103.53 | -15.01 | Upgrade
|
| EBT Excluding Unusual Items | -245.85 | -526.5 | -618.61 | -645.41 | -343.03 | -303.21 | Upgrade
|
| Other Unusual Items | -1.95 | - | -32.89 | -100.59 | - | -1.5 | Upgrade
|
| Pretax Income | -247.8 | -526.5 | -651.5 | -746 | -343.03 | -304.71 | Upgrade
|
| Income Tax Expense | 2.3 | 2.13 | 0.67 | 0.35 | 1.85 | - | Upgrade
|
| Net Income | -250.1 | -528.63 | -652.17 | -746.35 | -344.87 | -304.71 | Upgrade
|
| Net Income to Common | -250.1 | -528.63 | -652.17 | -746.35 | -344.87 | -304.71 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 119 | 106 | 84 | 75 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 119 | 106 | 84 | 75 | 62 | Upgrade
|
| Shares Change (YoY) | 6.08% | 11.84% | 25.70% | 12.32% | 20.78% | 14.40% | Upgrade
|
| EPS (Basic) | -2.03 | -4.45 | -6.15 | -8.84 | -4.59 | -4.90 | Upgrade
|
| EPS (Diluted) | -2.03 | -4.45 | -6.15 | -8.84 | -4.59 | -4.90 | Upgrade
|
| Free Cash Flow | -205.58 | -595.51 | -515.27 | -564.23 | -165.91 | -212.83 | Upgrade
|
| Free Cash Flow Per Share | -1.67 | -5.02 | -4.86 | -6.68 | -2.21 | -3.42 | Upgrade
|
| Gross Margin | 41.66% | -4.11% | - | - | 90.01% | - | Upgrade
|
| Operating Margin | -31.23% | -130.39% | -788.38% | -805.67% | -85.27% | - | Upgrade
|
| Profit Margin | -34.97% | -133.29% | -864.70% | -1121.27% | -137.59% | - | Upgrade
|
| Free Cash Flow Margin | -28.74% | -150.16% | -683.18% | -847.66% | -66.19% | - | Upgrade
|
| EBITDA | -221.51 | -515.34 | -593.06 | -534.9 | -213.09 | -287.78 | Upgrade
|
| EBITDA Margin | -30.97% | -129.94% | - | - | -85.02% | - | Upgrade
|
| D&A For EBITDA | 1.83 | 1.78 | 1.55 | 1.38 | 0.64 | 0.24 | Upgrade
|
| EBIT | -223.33 | -517.12 | -594.61 | -536.28 | -213.73 | -288.02 | Upgrade
|
| EBIT Margin | -31.23% | -130.39% | - | - | -85.27% | - | Upgrade
|
| Revenue as Reported | 715.22 | 396.59 | 75.42 | 66.56 | 250.65 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.